New Breakthroughs in Prostate Cancer Treatment
Early phase clinical trials suggest curcumin may prolong survival in low‑risk prostate cancer patients under active surveillance.
UT Southwestern highlights recent advances in treating prostate cancer, focusing on low‑risk disease management and toxicity reduction. A phase‑II curcumin trial under active surveillance shows promise in delaying progression, while a phase‑III study of SpaceOAR hydrogel demonstrates reduced rectal toxicity during radiation therapy. Additionally, TRITON2 evaluates the PARP inhibitor rucaparib in metastatic castration‑resistant prostate cancer with non‑BRCA DNA‑damage‑repair (DDR) gene alterations, suggesting broader therapeutic options for patients with DDR defects. These initiatives underscore the importance of early intervention, personalized medicine, and integrated clinical trials.
Prostate cancer remains a leading cause of morbidity and mortality among men. Early detection and intervention can improve survival while minimizing treatment‑related side effects. Curcumin offers a potentially nontoxic approach to slow tumor growth, SpaceOAR mitigates rectal damage from radiation, and rucaparib expands options for genetically defined metastatic disease. Together, these breakthroughs can transform patient outcomes and advance precision oncology.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience